The biological risk assessment (BRA) is a crucial component in ensuring the safety of medical devices that come into direct or indirect contact with the human body. As part of regulatory compliance, manufacturers must evaluate potential biological hazards associated with their devices. The ISO 10993 family of standards provides a comprehensive framework for conducting these assessments, addressing various biological endpoints based on the device’s intended use, duration of exposure, and materials used.
This article explores the key principles of biological risk assessment in accordance with ISO 10993, detailing the risk management approach, testing strategies, and compliance requirements to ensure the biocompatibility of medical devices.
We have been discussing extensively about biocompatibility, in particular about ISO 10993-1 , cytotoxicity, hemocompatility, residual ethylene oxide from sterilization and much more. In this article, we deal with the concept of biological risk assessment.
Understanding ISO 10993 and Its Scope
ISO 10993 is an internationally recognized series of standards that guide the biological evaluation of medical devices. The standard is closely aligned with ISO 14971, which governs risk management for medical devices. The biological risk assessment is a subset of the overall risk management process, focusing on:
- Identifying potential biological hazards
- Evaluating biological risks through testing and data analysis
- Mitigating risks through material selection and process control
The ISO 10993 family consists of multiple parts, each addressing specific biological endpoints such as cytotoxicity, sensitization, genotoxicity, systemic toxicity, and implantation effects. The most commonly referenced standard is ISO 10993-1, which outlines the general principles for biological evaluation and provides a risk-based approach to assessing biocompatibility.
The Biological Risk Assessment in ISO 10993-1
ISO 10993-1:2018 introduces a risk-based approach to biological evaluation, shifting away from a rigid testing matrix towards a scientifically justified assessment. Key steps in the biological risk assessment process include:
1. Material Characterization
Before conducting biological testing, a thorough material characterization is required under ISO 10993-18. This includes:
- Identifying chemical composition
- Assessing extractable and leachable substances
- Evaluating potential degradation products
Chemical characterization helps determine whether additional biological testing is necessary. If a material has an established safety profile with substantial historical data, further testing may be reduced or waived.
2. Toxicological Risk Assessment (TRA)
A Toxicological Risk Assessment (TRA) is performed to evaluate the potential health risks of identified chemical substances. ISO 10993-17 provides guidance on establishing acceptable exposure limits for identified compounds based on their toxicological profiles.
This assessment includes:
- Estimating worst-case exposure scenarios
- Comparing exposure levels with permissible exposure limits
- Conducting margin of safety calculations
If the toxicological risk assessment indicates potential hazards, additional testing may be required to confirm or mitigate risks.
3. Biological Testing Strategy
Once material characterization and toxicological assessment are completed, a tailored biological testing strategy is developed based on:
- Device classification (invasive, implantable, external-use, etc.)
- Type and duration of body contact (transient, short-term, long-term)
- Potential exposure to leachables and degradation products
ISO 10993-1 provides a biological evaluation matrix (Annex A) to help manufacturers select appropriate test categories, which may include:
- Cytotoxicity (ISO 10993-5): Assesses cell viability in response to device materials
- Sensitization (ISO 10993-10): Evaluates the potential for allergic reactions
- Irritation (ISO 10993-23): Determines the likelihood of tissue irritation upon exposure
- Systemic Toxicity (ISO 10993-11): Examines potential adverse effects on internal organs
- Genotoxicity (ISO 10993-3): Investigates potential DNA damage or mutagenic effects
- Implantation (ISO 10993-6): Evaluates local tissue response to implanted materials
Where possible, in vitro methods are preferred over in vivo animal testing, aligning with the principles of the 3Rs (Replacement, Reduction, Refinement) in biological evaluation.
Biological Risk Assessment and Risk Management
ISO 10993 requires that biological risk assessment be integrated into the broader risk management framework defined in ISO 14971. This ensures that all identified biological hazards are:
- Assessed for severity and probability
- Evaluated for risk acceptability
- Controlled through risk mitigation measures
The biological risk assessment should be documented within the Biological Evaluation Report (BER), which must include:
- Justification for material selection
- Summary of test results and toxicological assessments
- Rationale for any test omissions based on existing data
The BER must be reviewed and approved by qualified experts to ensure compliance with regulatory expectations.
Regulatory Expectations and Compliance
Regulatory bodies such as the FDA (U.S.), EMA (EU), and TGA (Australia) require manufacturers to demonstrate that their medical devices meet biocompatibility requirements before market approval. Key regulatory considerations include:
- FDA Guidance on ISO 10993: The FDA’s Use of ISO 10993-1 outlines how manufacturers should conduct biological risk assessments and submit biocompatibility data for 510(k) and PMA applications.
- EU MDR 2017/745: The EU Medical Device Regulation (MDR) emphasizes the need for a scientific risk-based approach rather than a simple checklist of tests.
- TGA (Australia) and CFDA (China): Similar biocompatibility requirements aligned with ISO 10993 and risk-based methodologies.
Compliance with these regulatory requirements ensures that medical devices are safe for human use and minimizes delays in market approval.
Common Challenges in Biological Risk Assessment
Conducting a biological risk assessment presents several challenges, including:
- Material Variability: Differences in raw materials and manufacturing processes can introduce variations in biocompatibility.
- Interpretation of Chemical Characterization Data: Identifying and quantifying leachables is complex and requires advanced analytical techniques.
- Regulatory Expectations for Justification of Test Omissions: Manufacturers must provide robust scientific reasoning when omitting biological tests.
- Ensuring Repeatability of Test Results: Variability in testing conditions can lead to inconsistent outcomes, requiring strict quality control measures.
Future Trends in Biological Risk Assessment
With advancements in alternative testing methods and digital risk modeling, the future of biological risk assessment is evolving. Key trends include:
- In silico modeling: Computational simulations to predict biocompatibility risks
- Advanced in vitro testing: Use of 3D cell cultures and organ-on-chip technologies
- Machine learning applications: AI-driven risk assessments for material selection
These advancements aim to reduce reliance on animal testing while improving the accuracy and efficiency of biological risk evaluations.
Conclusion
The biological risk assessment (BRA) is an essential component of ensuring medical device safety. ISO 10993 provides a comprehensive framework for evaluating biocompatibility through material characterization, toxicological risk assessment, and biological testing. Integrating ISO 10993 with ISO 14971 ensures that biological risks are systematically identified, assessed, and mitigated within a structured risk management framework.
For medical device manufacturers, a well-executed biological risk assessment is critical for regulatory compliance and market approval. By adopting a scientific risk-based approach, leveraging alternative testing methods, and staying updated on regulatory trends, manufacturers can ensure that their devices meet the highest safety and performance standards.
Subscribe to 4EasyReg Newsletter
4EasyReg is an online platform dedicated to Regulatory matters within the medical device, information security and AI-Based business.
We offer a wide range of documentation kits to support your compliance efforts towards a wide range of standards and regulations, such as ISO 13485, EU MDR, ISO 27001, ISO 42001 and much more. . Specifically, in our webshop you will find:
- ISO 13485 Documentation / Compliance Kit
- ISO 27001 Documentation / Compliance Kit
- ISO 42001 Documentation / Compliance Kit
- FDA Cybersecurity Documentation
Within our sister platform QualityMedDev Academy, a wide range of online & self-paced training courses is available, such as for example:
- Complaint Handling and Vigilance Reporting
- Artificial Intelligence in Medical Device. Regulatory Requirements
- Unique Device Identification (UDI) Requirements according to EU MDR
- Clinical Evaluation Process According to EU MDR
- Medical Device SW Verification & Validation
- Risk Management for Medical Devices
- Usability Evaluation for Medical Devices
As one of the leading online platforms in the medical device sector, 4EasyReg offers extensive support for regulatory compliance. Our services cover a wide range of topics, from EU MDR & IVDR to ISO 13485, encompassing risk management, biocompatibility, usability, software verification and validation, and assistance in preparing technical documentation for MDR compliance.
Do not hesitate to subscribe to our Newsletter!
